SR-121463. Sanofi-Synthélabo.

Abstract

Sanofi-Synthélabo (formerly Sanofi) is developing SR-121463, a vasopressin V, receptor antagonist, as a potential treatment for cardiovascular indications such as congestive heart failure (CHF) and hypertension [330073], [341858]. By September 2001, it had entered phase IIa trials for these indications [421268]. SR-121463 was in phase I clinical trials for CHF and hypertension in June 2001 [359231], [413342]. It was also being evaluated for the potential treatment of glaucoma but its development has been discontinued for this indication [367094]. In October 1999, Lehman Brothers predicted a 5% chance of the compound reaching market, with a launch anticipated in 2004 and potential peak sales of $100 million in 2012 [346267].

• Authors: A Martinez-Castelao
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 2 Issue 10 Pg. 1423-7 (Oct 2001) ISSN: 1472-4472 [Print] England
• PMID: 11890358 (Publication Type: Journal Article, Review)

Chemical References

• Antidiuretic Hormone Receptor Antagonists
• Antihypertensive Agents
• Morpholines
• Spiro Compounds
• satavaptan

Topics

• Animals
• Antidiuretic Hormone Receptor Antagonists
• Antihypertensive Agents (metabolism, pharmacology, therapeutic use, toxicity)
• Glaucoma (drug therapy)
• Heart Failure (drug therapy)
• Humans
• Hypertension (drug therapy)
• Morpholines (metabolism, pharmacology, therapeutic use, toxicity)
• Spiro Compounds (metabolism, pharmacology, therapeutic use, toxicity)
• Structure-Activity Relationship